As HDAC do not control replication of EHV-1 neurovirulent strains in CD172a+ cells, it is important to keep in mind that HDAC inhibitors may not be useful for horses with EHV-1-related neurological disorders or already showing symptoms. This evidence concerns the gene HDAC9 and nervous system disorder.